Bipolar Disorder Market Size, Share, Growth Report 2032

Bipolar Disorder Market

Bipolar Disorder Market - By Drug Class (Anticonvulsants, Mood Stabilizers, Antidepressant Drugs, Antipsychotic Drugs, and Antianxiety Drugs), By Mechanism Of Action (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2940 Published Date: Dec-2020 Status : Published

the global bipolar disorder market is expected to increase at a 2.4% CAGR from 5.2 billion USD in 2018 to 9.3 billion USD in 2025.

Bipolar Disorder Market: Overview

The Global Bipolar Disorder Market, which accrued revenue worth nearly 5.2 (USD Billion) in 2018 and is slated to garner earnings worth 9.3 (USD Billion) by 2025, is set to grow at a CAGR of 2.4% during the period from 2019 to 2025. The report offers a valuation and analysis of the Bipolar Disorder market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2015 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Global Bipolar Disorder Market SizeRequest Free Sample

Bipolar Disorder Market: Introduction

Bipolar disorder is a mental disorder resulting in extreme shifts in moods. Symptoms of bipolar disorder include elevated moods referred to as mania or hypomanic episodes and episodes of depression. These disorders are classified into bipolar disorder type I and bipolar disorder type II. Furthermore, bipolar disorder is the blend of three features encompassing complete genetic diathesis, distinct medical characteristics, and easy availing of lithium for treating the disorder. Apart from lithium, other anticonvulsants that are utilized for treating bipolar disorders are Tegretol, Lamictal, and valproic acid. While lithium and valproic acid are utilized for treating mania, Lamictal is used for treating depression.

Bipolar Disorder Market: Growth Drivers

Escalating awareness about diagnosing and treating bipolar disorders along with unmet requirements for treating the disorder will prompt the expansion of the bipolar disorder industry over the forecast timeline. Surging awareness about disorder among the public will promulgate market growth over the estimated timeline. Apart from this, technological breakthroughs in detecting genetic disorders and the rise in the medical treatment alternatives for these ailments are a few of the key factors driving the market expansion over the forecast timespan.

Furthermore, favorable government schemes such as the introduction of a bipolar disorder phenome database funded through the national institute of mental health are predicted to provide in-depth information pertaining to disease symptoms, thereby further embellishing the market trends. Nonetheless, strict laws launched by the government regarding the approval of anti-convulsants due to the side effects witnessed in the patients with its intake will put brakes on the growth of the bipolar disorder industry over the forecast timeline.

North American Market To Attain Highest Gains Over Forecast Timeline

The expansion of the industry in the sub-continent over the forecast timeline is owing to the surging occurrence of bipolar disorder in the countries like the U.S. and Canada. Additionally, the availability of strong healthcare infrastructure facilities and the rise in the occurrence of bipolar disorders will provide lucrative growth avenues for the market in the region over the forecast timespan. Citing an instance, National Alliance on Mental Illness stated that nearly one in every five adults in the U.S. suffered from a mental disorder each year, and this required hospitalization. All these factors will prompt the regional industry expansion over the forecast timeframe.

Key participants profiled in the report include Otsuka Holdings Co. Ltd; Janssen Pharmaceuticals; Pfizer Inc.; Novartis AG; Glaxo SmithKline (GSK); AbbVie Inc.; Eli Lilly; Allergan Plc.; and AstraZeneca.

The global bipolar disorder market is segmented as follows:

By drug class:

  • Antipsychotic drugs
  • Mood Stabilizers
  • Anticonvulsants
  • Antidepressant drugs
  • Antianxiety drugs

By the mechanism of action:

  • Serotonin Norepinephrine Reuptake Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Benzodiazepines
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Beta Blockers

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of The Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Escalating awareness about diagnosing and treating of bipolar disorders along with unmet requirements for treating the disorder will prompt the expansion of bipolar disorder industry over the forecast timeline. Surging awareness about disorder among the public will promulgate the market growth over the estimated timeline. Apart from this, technological breakthroughs in detecting genetic disorders and rise in the medical treatment alternatives for these ailments are few of the key factors driving the market expansion over the forecast timespan. Furthermore, favorable government schemes such as introduction of bipolar disorder phenome database funded through national institute of mental health is predicted to provide in-depth information pertaining to disease symptoms, thereby further embellishing the market trends.

According to Zion market research, the global Bipolar Disorder market, which accrued revenue worth nearly 5.2 (USD Billion) in 2018 and is slated to garner earnings worth 9.3 (USD Billion) by 2025, is set to grow at a CAGR of 2.4% during the period from 2019 to 2025.

North America is likely to make noteworthy contributions towards overall market revenue during 2019-2025. The surge in the expansion of market in the sub-continent over the estimated timespan is due to surging occurrence of the bipolar disorder in the countries like the U.S. and Canada. Additionally, availability of strong healthcare infrastructure facility and rise in the occurrence of bipolar disorders will provide lucrative growth avenues for the market in the region over the forecast timespan. Citing an instance, National Alliance on Mental Illness stated that nearly one in every five adults in the U.S. suffered from mental disorder each year and this required hospitalization. All these factors will prompt the regional industry expansion over the forecast timeframe.

The key players profiled in the report include Otsuka Holdings Co. Ltd; Janssen Pharmaceuticals; Pfizer Inc.; Novartis AG; Glaxo SmithKline (GSK); AbbVie Inc.; Eli Lilly; Allergan Plc.; and AstraZeneca.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed